Article Text

Download PDFPDF
Tamoxifen in patients with advanced epithelial ovarian cancer
  1. J. Van Der Velden,
  2. G. Gitsch,
  3. G. V. Wain,
  4. M. L. Friedlander and
  5. N. F. Hacker
  1. Gynaecological Cancer Centre, Royal Hospital for Women, Sydney, Australia
  1. Address for correspondence: Dr N. F. Hacker, Gynaecological Cancer Centre, Royal Hospital for Women, 188 Oxford Street, Sydney, NSW 2021, Australia.


Tamoxifen was administered to 30 patients with persistent or recurrent epithelial ovarian cancer following initial plantinum-based chemotherapy. Two complete remissions (lasting 41 months and 12 months, respectively) were documented (6.6%), while 10 patients (33.3%) had stabilization of disease for a mean duration of 11.5 months. Tamoxifen was not associated with any significant toxicity and is a reasonable therapeutic option for patients with persistent or recurrent ovarian cancer, although it is only associated with modest activity. This paper reviews our experience with tamoxifen and summarizes the world literature.

  • ovarian cancer
  • tamoxifen.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.